Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microwave ablation plus camrelizumab and bevacizumab for recurrent advanced liver cancer after surgery
ChiCTR2100044057Phase 2Recruiting
- Sponsor
- Second People's Hospital of Yunnan Province
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and bevacizumab in liver cancer, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), sponsored by Second People's Hospital of Yunnan Province. Primary endpoint: progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
camrelizumabbevacizumab
03
Conditions
liver cancerhepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2100044057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044057.